Publications by authors named "D Karavias"
HPB (Oxford)
November 2024
Article Synopsis
- Intraductal oncocytic papillary neoplasms (IOPNs) are now identified as distinct from intraductal papillary mucinous neoplasms (IPMNs), with limited information on their recurrence and survival outcomes.
- A study analyzed outcomes of 415 patients with invasive IOPNs and adenocarcinoma from IPMN over a median of 6 years, finding similar recurrence rates between invasive IOPNs and ductal A-IPMN, but poorer survival compared to colloid A-IPMN.
- The research concluded that invasive IOPNs behave like aggressive cancers, with adjuvant chemotherapy showing no significant impact on recurrence rates in any of the studied cancer types.
Ann Surg Oncol
October 2024
Article Synopsis
- The study examines the outcomes of different precursor epithelial subtypes of adenocarcinoma from intraductal papillary mucinous neoplasms (A-IPMN), focusing on clinical features and recurrence patterns among patients who underwent pancreatic surgery.
- A total of 297 patients were analyzed, revealing that gastric, pancreatobiliary, and mixed subtypes have similar outcomes that are worse than the intestinal subtype in terms of recurrence and overall survival.
- The research found that adjuvant chemotherapy specifically improved survival rates in the pancreatobiliary subtype, but not in gastric, intestinal, or mixed subtypes, indicating a potential area for further exploration in treatment strategies.
Article Synopsis
- - The study investigates factors affecting long-term survival and recurrence in patients with adenocarcinoma from intraductal papillary mucinous neoplasms, focusing on those who had pancreatic resection between 2010 and 2017 in Europe and Asia.
- - It analyzed data from 288 patients, revealing that 48% experienced recurrence within about 98 months, with 35% remaining disease-free at the 5-year mark.
- - Key negative predictors for long-term disease-free survival included multivisceral resection, tumor location in the pancreatic tail, poor differentiation, lymphovascular invasion, and perineural invasion, leading to the development of a predictive model with a good success rate.
Article Synopsis
- A study was conducted to determine the effects of adjuvant chemotherapy on patients with adenocarcinoma from intraductal papillary mucinous neoplasia after surgical resection, analyzing data from 459 patients across 18 centers between 2010 and 2020.
- The results showed that 59.9% of patients received various chemotherapy regimens, but there was no significant difference in recurrence rates or survival outcomes between those who received chemotherapy and those who did not.
- Overall, the study concluded that adjuvant chemotherapy does not appear to improve recurrence patterns or survival rates in this patient population.
Article Synopsis
- The study aimed to compare long-term cancer outcomes between patients with adenocarcinoma from intraductal papillary mucinous neoplasms (A-IPMN) and pancreatic ductal adenocarcinoma (PDAC) after surgical resection.
- Data revealed that A-IPMN patients generally had better survival rates and lower recurrence rates compared to PDAC patients, including longer median survival (39.0 months for A-IPMN vs. 19.5 months for PDAC).
- While A-IPMN showed higher rates of peritoneal and lung recurrence, PDAC had more locoregional recurrences, but overall, systemic recurrence rates were similar between the two groups.
